Mutual Sues West-Ward Over Gout Drug Patents

Law360, New York (April 25, 2011, 1:38 PM EDT) -- Mutual Pharmaceutical Co. Inc. filed suit Thursday in New Jersey alleging that West-Ward Pharmaceutical Corp.'s planned version of Mutual's gout treatment Colcrys infringes four patents.

Colcrys is the only oral drug containing the ingredient colchicine that has approval from the U.S. Food and Drug Administration to treat severe attacks of pain and inflammation associated with gout.

West-Ward marketed its own unapproved version of the drug for decades, but it was pulled from the market in October as part of an FDA crackdown on unapproved drugs. The...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.